Skip to main content
Evidence Snapshot

72 kDa type IV collagenase

CHEMBL333 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:01Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL333
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats 72 kDa type IV collagenase as ChEMBL target CHEMBL333, mapped to UniProt P08253. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
72 kDa type IV collagenase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL333
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P08253
72 kDa type IV collagenase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why 72 kDa type IV collagenase matters

As of 2026-09-13

72 kDa type IV collagenase is reviewed as 72 kDa type IV collagenase (UniProt P08253); 72 kDa type IV collagenase shows late clinical disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 6 approved drugs, 6114 compounds, and 678 assays, with lead potency reaching pChEMBL 11.0.

Disease context
breast cancer

72 kDa type IV collagenase shows late clinical disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include MARIMASTAT, REBIMASTAT.

Start review with breast cancer because it currently carries late clinical support. Linked drugs include MARIMASTAT, REBIMASTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Late clinical 2 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 6 approved drugs, 6114 compounds, and 678 assays for this target. The dominant activity type is IC50. CHEMBL92453 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL92453 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
6 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why 72 kDa type IV collagenase matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P08253, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why breast cancer is currently treated as late clinical support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

6114
Total Compounds
678
Total Assays
6
Approved Drugs
IC50: 5048.0, KI: 1362.0, KD: 11.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL92453
 11.0 Ki —
No preferred name
CHEMBL328092
 11.0 Ki —
No preferred name
CHEMBL92828
 11.0 Ki —
No preferred name
CHEMBL91655
 11.0 Ki —
No preferred name
CHEMBL74040
 11.0 Ki —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:01Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL333